EMA Authorised: Ordspono (odronextamab) — Regeneron Ireland Designated Activity Company (DAC)

View source ↗

Summary

The European Medicines Agency has authorised Ordspono (odronextamab) from Regeneron Ireland DAC for follicular lymphoma with conditional approval and orphan des…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Ordspono (odronextamab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Follicular. MAH: Regeneron Ireland Designated Activity Company (DAC). Decision date: 23/07/2025. Conditional approval. Orphan medicine